BNT162b2 mRNA transmission - Search Results

Year	Number of Results
2020	1
2021	52
2022	60
2023	25
2024	13
2025	1

1

Robust immune response to COVID-19 vaccination in the island population of Greenland.

Møller M, Friis-Hansen L, Kirkby N, Dilling-Hansen C, Andersson M, Vedsted P, Mølbak K, Koch A. Møller M, et al. Commun Med (Lond). 2024 Sep 6;4(1):173. doi: 10.1038/s43856-024-00602-y. Commun Med (Lond). 2024. PMID: 39242878 Free PMC article.

BACKGROUND: In Greenland, the COVID-19 pandemic was characterised by a late onset of community transmission and a low impact on the healthcare system, hypothesised as being partly due to a high uptake of vaccinations. ...The total plasma SARS-CoV-2 spike glycoprotein Ig an …

BACKGROUND: In Greenland, the COVID-19 pandemic was characterised by a late onset of community transmission and a low impact on the h …

2

Cytokine profile of anti-spike CD4(+)T cells predicts humoral and CD8(+)T cell responses after anti-SARS-CoV-2 mRNA vaccination.

Benhamouda N, Besbes A, Bauer R, Mabrouk N, Gadouas G, Desaint C, Chevrier L, Lefebvre M, Radenne A, Roelens M, Parfait B, Weiskopf D, Sette A, Gruel N, Courbebaisse M, Appay V, Paul S, Gorochov G, Ropers J, Lebbah S, Lelievre JD, Johannes L, Ulmer J, Lebeaux D, Friedlander G, De Lamballerie X, Ravel P, Kieny MP, Batteux F, Durier C, Launay O, Tartour E. Benhamouda N, et al. iScience. 2024 Jul 2;27(8):110441. doi: 10.1016/j.isci.2024.110441. eCollection 2024 Aug 16. iScience. 2024. PMID: 39104410 Free PMC article.

A cytokine signature composed of four cytokines (IL-2, TNF-alpha, IP10, IL-9) excluding IFN-gamma, and generated through machine learning, effectively predicted the CD8(+)T cell response following mRNA-1273 or BNT162b2 vaccine administration. Its applicabilit …

A cytokine signature composed of four cytokines (IL-2, TNF-alpha, IP10, IL-9) excluding IFN-gamma, and generated through machine learning, e …

3

High Transferability of Neutralizing Antibodies against SARS-CoV-2 to Umbilical Cord Blood in Pregnant Women Vaccinated with BNT162b2 XBB.1.5: A Retrospective Cohort Study.

Hayashi T, Sano K, Konishi I. Hayashi T, et al. Infect Dis Rep. 2024 May 27;16(3):481-490. doi: 10.3390/idr16030036. Infect Dis Rep. 2024. PMID: 38920892 Free PMC article.

These variants can evade the immune response triggered by traditional mRNA-based COVID-19 vaccines, such as BNT162b2. Therefore, vaccination with BNT162b2 XBB.1.5, which provides protection against omicron-type SARS-CoV-2 variants, is recommended. METHODS: Th …

These variants can evade the immune response triggered by traditional mRNA-based COVID-19 vaccines, such as BNT162b2. Therefor …

4

Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study.

Amstutz A, Chammartin F, Audigé A, Eichenberger AL, Braun DL, Amico P, Stoeckle MP, Hasse B, Papadimitriou-Olivgeris M, Manuel O, Bongard C, Schuurmans MM, Hage R, Damm D, Tamm M, Mueller NJ, Rauch A, Günthard HF, Koller MT, Schönenberger CM, Griessbach A, Labhardt ND, Kouyos RD, Trkola A, Kusejko K, Bucher HC, Abela IA, Briel M, Speich B; Swiss HIV Cohort Study; Swiss Transplant Cohort. Amstutz A, et al. J Infect Dis. 2024 Oct 16;230(4):e847-e859. doi: 10.1093/infdis/jiae291. J Infect Dis. 2024. PMID: 38848312 Free PMC article. Clinical Trial.

BACKGROUND: Bivalent messenger RNA (mRNA) vaccines, designed to combat emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, incorporate ancestral strains and a new variant. Our study assessed the immune response in previously vaccin …

BACKGROUND: Bivalent messenger RNA (mRNA) vaccines, designed to combat emerging severe acute respiratory syndrome coron …

5

How effective is the BNT162b2 mRNA vaccine against SARS-CoV-2 transmission and infection? A national programme analysis in Monaco, July 2021 to September 2022.

Althaus T, Overton CE, Devaux I, House T, Lapouze A, Troel A, Vanzo B, Laroche M, Bordero A, Jorgensen P, Pebody R, Voiglio EJ. Althaus T, et al. BMC Med. 2024 Jun 5;22(1):227. doi: 10.1186/s12916-024-03444-6. BMC Med. 2024. PMID: 38840159 Free PMC article.

BACKGROUND: We quantified SARS-CoV-2 dynamics in different community settings and the direct and indirect effect of the BNT162b2 mRNA vaccine in Monaco for different variants of concern (VOC). METHODS: Between July 2021 and September 2022, we prospectively in …

BACKGROUND: We quantified SARS-CoV-2 dynamics in different community settings and the direct and indirect effect of the BNT162b2 m …

6

Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination.

Gorochov G, Ropers J, Launay O, Dorgham K, da Mata-Jardin O, Lebbah S, Durier C, Bauer R, Radenne A, Desaint C, Vieillard LV, Rekacewicz C, Lachatre M, Parfait B, Batteux F, Hupé P, Ninove L, Lefebvre M, Conrad A, Dussol B, Maakaroun-Vermesse Z, Melica G, Nicolas JF, Verdon R, Kiladjian JJ, Loubet P, Schmidt-Mutter C, Dualé C, Ansart S, Botelho-Nevers E, Lelièvre JD, de Lamballerie X, Kieny MP, Tartour E, Paul S. Gorochov G, et al. JAMA Netw Open. 2024 Apr 1;7(4):e248051. doi: 10.1001/jamanetworkopen.2024.8051. JAMA Netw Open. 2024. PMID: 38652471 Free PMC article.

IMPORTANCE: There is still considerable controversy in the literature regarding the capacity of intramuscular messenger RNA (mRNA) vaccination to induce a mucosal immune response. OBJECTIVE: To compare serum and salivary IgG and IgA levels among mRNA-v …

IMPORTANCE: There is still considerable controversy in the literature regarding the capacity of intramuscular messenger RNA ( …

7

Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategy.

Sieghart D, Hana CA, Dürrschmid C, Heinz LX, Haslacher H, Zlesak M, Piccini G, Manenti A, Montomoli E, Jorda A, Fedrizzi C, Hasenoehrl T, Zdravkovic A, Anderle K, Wiedermann U, Drapalik S, Steinbrecher H, Bergmann F, Firbas C, Jordakieva G, Wagner B, Leonardi M, Pierleoni G, Ballini M, Benincasa L, Marchi S, Trombetta C, Perkmann T, Crevenna R, Zeitlinger M, Bonelli M, Aletaha D, Radner H. Sieghart D, et al. J Clin Virol. 2024 Aug;173:105661. doi: 10.1016/j.jcv.2024.105661. Epub 2024 Feb 28. J Clin Virol. 2024. PMID: 38503118 Clinical Trial.

BACKGROUND: Various SARS-CoV-2 variants of concerns (VOCs) characterized by higher transmissibility and immune evasion have emerged. Despite reduced vaccine efficacy against VOCs, currently available vaccines provide protection. ...RESULTS: Our main model including …

BACKGROUND: Various SARS-CoV-2 variants of concerns (VOCs) characterized by higher transmissibility and immune evasion have emerged. …

8

Incidence of COVID-19 mRNA vaccine symptomatic breakthrough infections during Omicron circulation in adults with or without infection prior to vaccination.

Durier C, Ninove L, van der Werf S, Lefebvre M, Desaint C, Bauer R, Attia M, Lecompte AS, Lachatre M, Maakaroun-Vermesse Z, Nicolas JF, Verdon R, Kiladjian JJ, Loubet P, Schmidt-Mutter C, Corbin V, Ansart S, Melica G, Resch M, Netzer E, Kherabi Y, Tardieu R, Lelièvre JD, Tartour E, Meyer L, de Lamballerie X, Launay O; ANRS002S CoviCompareP group. Durier C, et al. Infect Dis Now. 2024 Aug;54(5):104886. doi: 10.1016/j.idnow.2024.104886. Epub 2024 Mar 16. Infect Dis Now. 2024. PMID: 38494117 Free article.

OBJECTIVES: COVID-19 vaccine breakthrough infections were frequently reported during circulation of the Omicron variant. The ANRS|MIE CoviCompareP study investigated these infections in adults vaccinated and boosted with BNT162b2 [Pfizer-BioNTech] and with/without S …

OBJECTIVES: COVID-19 vaccine breakthrough infections were frequently reported during circulation of the Omicron variant. The ANRS|MIE …

9

Immunogenicity and Tolerance of BNT162b2 mRNA Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Patients.

Ben Khlil AA, Zamali I, Belloumi D, Gdoura M, Kharroubi G, Marzouki S, Dachraoui R, Ben Yaiche I, Bchiri S, Hamdi W, Gharbi M, Ben Hmid A, Samoud S, Galai Y, Torjmane L, Ladeb S, Bettaieb J, Triki H, Ben Abdeljelil N, Ben Othman T, Ben Ahmed M. Ben Khlil AA, et al. Vaccines (Basel). 2024 Feb 8;12(2):174. doi: 10.3390/vaccines12020174. Vaccines (Basel). 2024. PMID: 38400157 Free PMC article.

BACKGROUND: Allogeneic hematopoietic stem cell transplantation (ASCT) induces acquired immunodeficiency, potentially altering vaccine response. Herein, we aimed to explore the clinical tolerance and the humoral and cellular immune responses following anti-SARS-CoV-2 vaccin …

BACKGROUND: Allogeneic hematopoietic stem cell transplantation (ASCT) induces acquired immunodeficiency, potentially altering vaccine …

10

An intranasal live-attenuated SARS-CoV-2 vaccine limits virus transmission.

Adler JM, Martin Vidal R, Langner C, Vladimirova D, Abdelgawad A, Kunecova D, Lin X, Nouailles G, Voss A, Kunder S, Gruber AD, Wu H, Osterrieder N, Kunec D, Trimpert J. Adler JM, et al. Nat Commun. 2024 Feb 2;15(1):995. doi: 10.1038/s41467-024-45348-2. Nat Commun. 2024. PMID: 38307868 Free PMC article.

Here we compare the efficacy of a mucosal, replication-competent yet fully attenuated virus vaccine, sCPD9-deltaFCS, and the monovalent mRNA vaccine BNT162b2 in preventing transmission of SARS-CoV-2 variants B.1 and Omicron BA.5 in two scenarios …

Here we compare the efficacy of a mucosal, replication-competent yet fully attenuated virus vaccine, sCPD9-deltaFCS, and the monovale …

11

Vaccinating against a Novel Pathogen: A Critical Review of COVID-19 Vaccine Effectiveness Evidence.

Black B, Thaw DB. Black B, et al. Microorganisms. 2023 Dec 31;12(1):89. doi: 10.3390/microorganisms12010089. Microorganisms. 2023. PMID: 38257917 Free PMC article. Review.

Almost all were vaccinated, infected, or often both. We review the evidence on COVID-19 vaccine effectiveness (VE) and waning effectiveness over time and the relative effectiveness of the four principal vaccines used in developed Western countries: BNT162b2 (Pfizer- …

Almost all were vaccinated, infected, or often both. We review the evidence on COVID-19 vaccine effectiveness (VE) and waning effecti …

12

Biodistribution of RNA Vaccines and of Their Products: Evidence from Human and Animal Studies.

Pateev I, Seregina K, Ivanov R, Reshetnikov V. Pateev I, et al. Biomedicines. 2023 Dec 26;12(1):59. doi: 10.3390/biomedicines12010059. Biomedicines. 2023. PMID: 38255166 Free PMC article. Review.

Explosive developments in mRNA vaccine technology in the last decade have made it possible to achieve great success in clinical trials of mRNA vaccines to prevent infectious diseases and develop cancer treatments and mRNA-based gene therapy products. . …

Explosive developments in mRNA vaccine technology in the last decade have made it possible to achieve great success in clinica …

13

Insufficient anti-spike RBD IgA responses after triple vaccination with intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2.

Yoshimura M, Sakamoto A, Ozuru R, Kurihara Y, Itoh R, Ishii K, Shimizu A, Chou B, Sechi Y, Fujikane A, Nabeshima S, Hiromatsu K. Yoshimura M, et al. Heliyon. 2023 Dec 13;10(1):e23595. doi: 10.1016/j.heliyon.2023.e23595. eCollection 2024 Jan 15. Heliyon. 2023. PMID: 38187240 Free PMC article.

OBJECTIVES: This study aims to examine whether the parenterally administered mRNA-based COVID-19 vaccines can induce sufficient mucosal-type IgA responses to prevent SARS-CoV-2 transmission. METHODS: We examined the longitudinal kinetics of SARS-CoV-2 spike RBD-spec …

OBJECTIVES: This study aims to examine whether the parenterally administered mRNA-based COVID-19 vaccines can induce sufficient mucos …

14

COVID-19: From emerging variants to vaccination.

Senevirathne TH, Wekking D, Swain JWR, Solinas C, De Silva P. Senevirathne TH, et al. Cytokine Growth Factor Rev. 2024 Apr;76:127-141. doi: 10.1016/j.cytogfr.2023.11.005. Epub 2023 Dec 9. Cytokine Growth Factor Rev. 2024. PMID: 38135574 Review.

These mutated forms of SARS-CoV-2, otherwise known as variants, were categorized as variants of interest (VOI) or variants of concern (VOC) based on the increased risk of transmissibility, disease severity, immune escape, decreased effectiveness of current social measures, …

These mutated forms of SARS-CoV-2, otherwise known as variants, were categorized as variants of interest (VOI) or variants of concern (VOC) …

15

The relationship between the number of COVID-19 vaccines and infection with Omicron ACE2 inhibition at 18-months post initial vaccination in an adult cohort of Canadian paramedics.

Yap J, Kayda I, Asamoah-Boaheng M, Haig S, Kirkham T, Cheskes S, Demers P, Goldfarb D, Grunau BE. Yap J, et al. Access Microbiol. 2023 Nov 28;5(11):000725.v3. doi: 10.1099/acmi.0.000725.v3. eCollection 2023. Access Microbiol. 2023. PMID: 38074102 Free PMC article.

We investigated neutralizing antibody (NtAb) response against wild-type (WT) Wuhan Hu-1 and Omicron BA.4/5 lineages based on the number of doses and past SARS-CoV-2 infection, at 18 months post-initial vaccination (with a Wuhan Hu-1 platform mRNA vaccine [BNT162b …

We investigated neutralizing antibody (NtAb) response against wild-type (WT) Wuhan Hu-1 and Omicron BA.4/5 lineages based on the number of d …

16

Effectiveness of BNT162b2 and ChAdOx1 against SARS-CoV-2 household transmission: a prospective cohort study in England.

Clifford S, Waight P, Hackman J, Hué S, Gower CM, Kirsebom FC, Skarnes C, Letley L, Lopez Bernal J, Andrews N, Flasche S, Miller E. Clifford S, et al. Wellcome Open Res. 2023 Nov 2;8:96. doi: 10.12688/wellcomeopenres.17995.2. eCollection 2023. Wellcome Open Res. 2023. PMID: 38058535 Free PMC article.

BACKGROUND: The ability of SARS-CoV-2 vaccines to protect against infection and onward transmission determines whether immunisation can control global circulation. We estimated the effectiveness of Pfizer-BioNTech mRNA vaccine (BNT162b2) and Oxford Ast …

BACKGROUND: The ability of SARS-CoV-2 vaccines to protect against infection and onward transmission determines whether immunisation c …

17

Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children.

Bellusci L, Grubbs G, Sait S, Yonker LM, Randolph AG, Novak T, Kobayashi T; Overcoming COVID−19 Investigators; Khurana S. Bellusci L, et al. Nat Commun. 2023 Dec 1;14(1):7952. doi: 10.1038/s41467-023-43152-y. Nat Commun. 2023. PMID: 38040697 Free PMC article.

Emergence of highly transmissible Omicron subvariants led to increased SARS-CoV-2 infection and disease in children. ...An age-associated effect on neutralizing antibodies is observed against SARS-CoV-2 following acute COVID-19 or vaccination. The primary series BNT162b …

Emergence of highly transmissible Omicron subvariants led to increased SARS-CoV-2 infection and disease in children. ...An age-associ …

18

Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2).

Griessbach A, Chammartin F, Abela IA, Amico P, Stoeckle MP, Eichenberger AL, Hasse B, Braun DL, Schuurmans MM, Müller TF, Tamm M, Audigé A, Mueller NJ, Rauch A, Günthard HF, Koller MT, Trkola A, Epp S, Amstutz A, Schönenberger CM, Taji Heravi A, Papadimitriou-Olivgeris M, Casutt A, Manuel O, Kusejko K, Bucher HC, Briel M, Speich B; Swiss HIV Cohort Study and the Swiss Transplant Cohort Study. Griessbach A, et al. Open Forum Infect Dis. 2023 Nov 3;10(11):ofad536. doi: 10.1093/ofid/ofad536. eCollection 2023 Nov. Open Forum Infect Dis. 2023. PMID: 38023564 Free PMC article.

BACKGROUND: After basic immunization with 2 mRNA SARS-CoV-2 vaccine doses, only a small proportion of patients who are severely immunocompromised generate a sufficient antibody response. ...RESULTS: Nearly all participants (97.2% [95% CI, 95.9%-98.6%], 564/580) had …

BACKGROUND: After basic immunization with 2 mRNA SARS-CoV-2 vaccine doses, only a small proportion of patients who are severel …

19

Dynamics of Serum-Neutralizing Antibody Responses in Vaccinees through Multiple Doses of the BNT162b2 Vaccine.

Sheehan J, Ardizzone CM, Khanna M, Trauth AJ, Hagensee ME, Ramsay AJ. Sheehan J, et al. Vaccines (Basel). 2023 Nov 15;11(11):1720. doi: 10.3390/vaccines11111720. Vaccines (Basel). 2023. PMID: 38006052 Free PMC article.

SARS-CoV-2 mRNA vaccines are administered as effective prophylactic measures for reducing virus transmission rates and disease severity. ...A 16-member cohort of healthy SARS-CoV-2 naive participants were enrolled in this study during a three-dose BNT162b2 …

SARS-CoV-2 mRNA vaccines are administered as effective prophylactic measures for reducing virus transmission rates and disease …

20

Adjuvant activities of immunostimulating natural products: Astragalus membranaceus (Fisch.) Bge. and Coriolus versicolor in BNT162b2 vaccination against COVID-19 infection.

Chan BC, Li P, Tsang MS, Sung JC, Kwong KW, Zheng T, Hon SS, Lau CP, Ho RC, Chen F, Lau CB, Leung PC, Wong CK. Chan BC, et al. J Leukoc Biol. 2024 Jan 5;115(1):177-189. doi: 10.1093/jleuko/qiad106. J Leukoc Biol. 2024. PMID: 37713617

Using BALB/c mice, orally administrated AM and CV (1,384 and 742 mg/kg/d) for 4 d after vaccination, respectively, could enhance (1) the immunoglobulin G binding activities of BNT162b2 vaccination against ancestral and Delta SARS-CoV-2 spike proteins by 5.8- and 4.3-fold, …

Using BALB/c mice, orally administrated AM and CV (1,384 and 742 mg/kg/d) for 4 d after vaccination, respectively, could enhance (1) the imm …

21

SARS-CoV-2 mRNA Vaccine Elicits Sustained T Cell Responses Against the Omicron Variant in Adolescents.

Choi S, Kim SH, Han MS, Yoon Y, Kim YK, Cho HK, Yun KW, Song SH, Ahn B, Kim YK, Choi SH, Choe YJ, Lim H, Choi EB, Kim K, Hyeon S, Lim HJ, Kim BC, Lee YK, Choi EH, Shin EC, Lee H. Choi S, et al. Immune Netw. 2023 Aug 11;23(4):e33. doi: 10.4110/in.2023.23.e33. eCollection 2023 Aug. Immune Netw. 2023. PMID: 37670807 Free PMC article.

Vaccine-induced immunity and longevity have not been well defined in this population. Therefore, we aimed to analyze humoral and cellular immune responses against ancestral and SARS-CoV-2 variants after two shots of the BNT162b2 vaccine in healthy adolescents …

Vaccine-induced immunity and longevity have not been well defined in this population. Therefore, we aimed to analyze humoral and cell …

22

Effectiveness of BNT162b2 and Sinovac vaccines against the transmission of SARS-CoV-2 during Omicron-predominance in Hong Kong: A retrospective cohort study of COVID-19 cases.

Zhao S, Guo Z, Sun S, Hung CT, Leung EYM, Wei Y, Wang H, Li K, Yam CHK, Chow TY, Gao J, Jia KM, Chong KC, Yeoh EK. Zhao S, et al. J Clin Virol. 2023 Sep;166:105547. doi: 10.1016/j.jcv.2023.105547. Epub 2023 Jul 10. J Clin Virol. 2023. PMID: 37453162

The effectiveness of mRNA vaccine (BNT162b2) and inactivated vaccine (Sinovac) against transmission of BA.2 variants was estimated using zero-inflated negative binomial regression models. RESULTS: Vaccine effectiveness against transmis …

The effectiveness of mRNA vaccine (BNT162b2) and inactivated vaccine (Sinovac) against transmission of BA …

23

Insights into the Structure of Comirnaty Covid-19 Vaccine: A Theory on Soft, Partially Bilayer-Covered Nanoparticles with Hydrogen Bond-Stabilized mRNA-Lipid Complexes.

Szebeni J, Kiss B, Bozó T, Turjeman K, Levi-Kalisman Y, Barenholz Y, Kellermayer M. Szebeni J, et al. ACS Nano. 2023 Jul 25;17(14):13147-13157. doi: 10.1021/acsnano.2c11904. Epub 2023 Jul 7. ACS Nano. 2023. PMID: 37417667 Free PMC article.

To fill this gap, we used a combination of atomic force microscopy (AFM), dynamic light scattering (DLS), transmission electron microscopy (TEM), cryogenic transmission electron microscopy (cryo-TEM), and the determination of the intra-LNP pH gradient to analyze the …

To fill this gap, we used a combination of atomic force microscopy (AFM), dynamic light scattering (DLS), transmission electron micro …

24

Antibody responses to mRNA versus non-mRNA COVID vaccines among the Mongolian population.

Sereejav E, Sandagdorj A, Bazarjav P, Ganbold S, Enkhtuvshin A, Tsedenbal N, Namuuntsetseg B, Chimedregzen K, Badarch D, Otgonbayar D, Artbazar B, Enebish O, Tsevegmid E, Baigude H, Batzorig U, Batmunkh B, Jantsansengee B, Tserendorj C, Dorjderem B, Tsolmon B, Ganbold T. Sereejav E, et al. IJID Reg. 2023 Sep;8:1-8. doi: 10.1016/j.ijregi.2023.05.002. Epub 2023 May 14. IJID Reg. 2023. PMID: 37309454 Free PMC article.

The level of anti-SARS-CoV-2 S-RBD protein IgG was significantly increased in the ChAdOx1 n-CoV-19, Gam-COVID-Vac, and BNT162b2 vaccines groups as compared to the unvaccinated group. Participants in the BNT162b2 vaccine group had higher ACE2 inhibition effici …

The level of anti-SARS-CoV-2 S-RBD protein IgG was significantly increased in the ChAdOx1 n-CoV-19, Gam-COVID-Vac, and BNT162b2 vacci …

25

Long-term Real-world Protection Afforded by Third mRNA Doses Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections, Coronavirus Disease 19-related Emergency Attendances and Hospitalizations Amongst Older Singaporeans During an Omicron XBB Wave.

Wee LE, Pang D, Chiew C, Tan J, Lee V, Ong B, Lye DC, Tan KB. Wee LE, et al. Clin Infect Dis. 2023 Oct 13;77(8):1111-1119. doi: 10.1093/cid/ciad345. Clin Infect Dis. 2023. PMID: 37280047

We report estimates of protection against symptomatic infection, emergency department (ED) attendances and hospitalizations up to and beyond 360 days post-receipt of booster messenger RNA (mRNA) vaccines among Singaporeans aged 60 years during an Omicron XBB …

We report estimates of protection against symptomatic infection, emergency department (ED) attendances and hospitalizations up to and beyond …

26

Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study.

Nelli F, Fabbri A, Virtuoso A, Giannarelli D, Giron Berrios JR, Marrucci E, Fiore C, Schirripa M, Signorelli C, Chilelli MG, Primi F, Pessina G, Natoni F, Silvestri MA, Ruggeri EM. Nelli F, et al. Curr Oncol. 2023 May 17;30(5):5103-5115. doi: 10.3390/curroncol30050386. Curr Oncol. 2023. PMID: 37232844 Free PMC article.

There is a paucity of data on the effects of COVID-19 outbreaks on long-term survival outcomes in this population. (2) Methods: We enrolled 230 cancer patients who were on active treatment for advanced disease and had received booster dosing of an mRNA-BNT162b2 v …

There is a paucity of data on the effects of COVID-19 outbreaks on long-term survival outcomes in this population. (2) Methods: We enrolled …

27

Immune-Mediated Necrotizing Myopathy With Concurrent Statin Use After Routine COVID-19 Inoculation: A Case Report.

Mufti Z, Dietz N, Pearson L, Fortuny E, Mettille J, Ding D, Brown M, Mufti H. Mufti Z, et al. Cureus. 2023 Apr 20;15(4):e37876. doi: 10.7759/cureus.37876. eCollection 2023 Apr. Cureus. 2023. PMID: 37223148 Free PMC article.

Many case reports have documented post-SARS-CoV-2 virus effects; however, this case highlights the possibility of a less commonly described neurological manifestation possibly related to the BNT162b2 mRNA Pfizer vaccine. There is scant literature on immune-me …

Many case reports have documented post-SARS-CoV-2 virus effects; however, this case highlights the possibility of a less commonly described …

28

Vaccine effectiveness against transmission of alpha, delta and omicron SARS-COV-2-infection, Belgian contact tracing, 2021-2022.

Braeye T, Catteau L, Brondeel R, van Loenhout JAF, Proesmans K, Cornelissen L, Van Oyen H, Stouten V, Hubin P, Billuart M, Djiena A, Mahieu R, Hammami N, Van Cauteren D, Wyndham-Thomas C. Braeye T, et al. Vaccine. 2023 May 11;41(20):3292-3300. doi: 10.1016/j.vaccine.2023.03.069. Epub 2023 Apr 5. Vaccine. 2023. PMID: 37085456 Free PMC article.

OBJECTIVES: Vaccine effectiveness against transmission (VET) of SARS-CoV-2-infection can be estimated from secondary attack rates observed during contact tracing. We estimated VET, the vaccine-effect on infectiousness of the index case and susceptibility of t …

OBJECTIVES: Vaccine effectiveness against transmission (VET) of SARS-CoV-2-infection can be estimated from secondary attack ra …

29

An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters.

Deng S, Liu Y, Tam RC, Chen P, Zhang AJ, Mok BW, Long T, Kukic A, Zhou R, Xu H, Song W, Chan JF, To KK, Chen Z, Yuen KY, Wang P, Chen H. Deng S, et al. Nat Commun. 2023 Apr 12;14(1):2081. doi: 10.1038/s41467-023-37697-1. Nat Commun. 2023. PMID: 37045873 Free PMC article.

Immune responses and protection against virus challenge following intranasal administration of DelNS1-RBD4N-DAF vaccines were analyzed in mice and compared with intramuscular injection of the BioNTech BNT162b2 mRNA vaccine in hamsters. DelNS1-RBD4N-DAF LAIVs …

Immune responses and protection against virus challenge following intranasal administration of DelNS1-RBD4N-DAF vaccines were analyzed in mi …

30

Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2).

Griessbach A, Chammartin F, Abela IA, Amico P, Stoeckle MP, Eichenberger AL, Hasse B, Braun DL, Schuurmans MM, Müller TF, Tamm M, Audigé A, Mueller NJ, Rauch A, Günthard HF, Koller MT, Trkola A, Epp S, Amstutz A, Schönenberger CM, Taji Heravi A, Kusejko K, Bucher HC, Briel M, Speich B; Swiss HIV Cohort Study and the Swiss Transplant Cohort Study. Griessbach A, et al. Open Forum Infect Dis. 2023 Mar 30;10(4):ofad150. doi: 10.1093/ofid/ofad150. eCollection 2023 Apr. Open Forum Infect Dis. 2023. PMID: 37035486 Free PMC article.

Extension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response of the third dose of Moderna mRNA-1273 vaccine (95.3% [95% confidence interval {CI}, 91.9%-98.7%]) compared to Pfizer-BioNTech BNT162b2 …

Extension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response of the third do …

31

Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters.

Nouailles G, Adler JM, Pennitz P, Peidli S, Teixeira Alves LG, Baumgardt M, Bushe J, Voss A, Langenhagen A, Langner C, Martin Vidal R, Pott F, Kazmierski J, Ebenig A, Lange MV, Mühlebach MD, Goekeri C, Simmons S, Xing N, Abdelgawad A, Herwig S, Cichon G, Niemeyer D, Drosten C, Goffinet C, Landthaler M, Blüthgen N, Wu H, Witzenrath M, Gruber AD, Praktiknjo SD, Osterrieder N, Wyler E, Kunec D, Trimpert J. Nouailles G, et al. Nat Microbiol. 2023 May;8(5):860-874. doi: 10.1038/s41564-023-01352-8. Epub 2023 Apr 3. Nat Microbiol. 2023. PMID: 37012419 Free PMC article.

Future control of the pandemic requires improved vaccines with high efficacy against newly emerging SARS-CoV-2 variants and the ability to reduce virus transmission. Here we compare immune responses and preclinical efficacy of the mRNA vaccine BNT162b2 …

Future control of the pandemic requires improved vaccines with high efficacy against newly emerging SARS-CoV-2 variants and the ability to r …

32

Immunity of Heterologously and Homologously Boosted or Convalescent Individuals Against Omicron BA.1, BA.2, and BA.4/5 Variants.

Jäger M, Diem G, Sahanic S, Fux V, Griesmacher A, Lass-Flörl C, Wilflingseder D, Tancevski I, Posch W. Jäger M, et al. J Infect Dis. 2023 Jul 14;228(2):160-168. doi: 10.1093/infdis/jiad057. J Infect Dis. 2023. PMID: 36869832 Free PMC article.

Individuals in the first group were vaccinated twice with ChAdOx1 and boosted with a messenger RNA (mRNA) vaccine (BNT162b2 or mRNA-1273); the second group included triple mRNA--vaccinated participants, and the third group, twice-v …

Individuals in the first group were vaccinated twice with ChAdOx1 and boosted with a messenger RNA (mRNA) vaccine …

33

Evaluation of antibody response anti SARS-Cov-2: A retrospective observational study (Marche-Italy).

Baglioni I, Galli A, Gatti C, Tufoni S, Rocchi R, Lattanzi F, Toia F, Santarelli A, Marcelli S. Baglioni I, et al. Ig Sanita Pubbl. 2023 Jan-Feb;80(1):13-26. Ig Sanita Pubbl. 2023. PMID: 36749593

DISCUSSION AND CONCLUSION: This study leads to the conclusion that the second dose of vaccine Sars-Cov-2 vaccine mRNA BNT162b2 vaccine allows a consistent antibody response. Further multicentric studies are needed to investigate the antibody res …

DISCUSSION AND CONCLUSION: This study leads to the conclusion that the second dose of vaccine Sars-Cov-2 vaccine mRNA …

34

Evaluation of post-vaccination immunoglobulin G antibodies and T-cell immune response after inoculation with different types and doses of SARS-CoV-2 vaccines: A retrospective cohort study.

Al-Rifai RH, Alhosani F, Abuyadek R, Atef S, Donnelly JG, Leinberger-Jabari A, Ahmed LA, Altrabulsi B, Alatoom A, Alsuwaidi AR, AbdelWareth L. Al-Rifai RH, et al. Front Med (Lausanne). 2023 Jan 10;9:1092646. doi: 10.3389/fmed.2022.1092646. eCollection 2022. Front Med (Lausanne). 2023. PMID: 36703898 Free PMC article.

BBIBP-CorV (Sinopharm) was the most commonly used vaccine (92.1%), followed by rAd26-S + rAd5-S (Sputnik V Gam-COVID-Vac) (1.5%) and BNT162b2 (Pfizer-BioNTech) (0.3%). ...CONCLUSION: Achieving and maintaining a high blood concentration of protective immune biomarker …

BBIBP-CorV (Sinopharm) was the most commonly used vaccine (92.1%), followed by rAd26-S + rAd5-S (Sputnik V Gam-COVID-Vac) (1.5%) and …

35

SARS-CoV-2 Omicron BA.4/BA.5 Mutations in Spike Leading to T Cell Escape in Recently Vaccinated Individuals.

Emmelot ME, Vos M, Boer MC, Rots NY, van Els CACM, Kaaijk P. Emmelot ME, et al. Viruses. 2022 Dec 29;15(1):101. doi: 10.3390/v15010101. Viruses. 2022. PMID: 36680141 Free PMC article.

T cells isolated from 10 subjects, who were recently vaccinated with mRNA-based BNT162b2, were tested for functional cross-reactivity between epitopes of ancestral SARS-CoV-2 spike and the Omicron BA.4/BA.5 spike counterparts. ...These results should be considered f …

T cells isolated from 10 subjects, who were recently vaccinated with mRNA-based BNT162b2, were tested for functional cross-rea …

36

Infection by SARS-CoV-2 with alternate frequencies of mRNA vaccine boosting.

Townsend JP, Hassler HB, Dornburg A. Townsend JP, et al. J Med Virol. 2023 Feb;95(2):e28461. doi: 10.1002/jmv.28461. J Med Virol. 2023. PMID: 36602045

One of the most consequential unknowns of the COVID-19 pandemic is the frequency at which vaccine boosting provides sufficient protection from infection. We quantified the statistical likelihood of breakthrough infections over time following different boosting schedules wi …

One of the most consequential unknowns of the COVID-19 pandemic is the frequency at which vaccine boosting provides sufficient protec …

37

Acute Retinal Pigment Epitheliitis following Vaccination.

Sasajima H, Zako M, Aoyagi A, Ueta Y, Suzuki T. Sasajima H, et al. Case Rep Ophthalmol. 2022 Nov 10;13(3):823-828. doi: 10.1159/000527598. eCollection 2022 Sep-Dec. Case Rep Ophthalmol. 2022. PMID: 36601646 Free PMC article.

He had received the second dose of coronavirus disease 2019 vaccination (BNT162b2 mRNA, Pfizer-BioNTech) 1 month prior, following which he developed a low-grade fever of 37.3-37.5C for 2 days accompanied by joint pain. ...Fluorescein angiography revealed slight t …

He had received the second dose of coronavirus disease 2019 vaccination (BNT162b2 mRNA, Pfizer-BioNTech) 1 month prior, follow …

38

The BNT162b2 vaccine induces humoral and cellular immune memory to SARS-CoV-2 Wuhan strain and the Omicron variant in children 5 to 11 years of age.

Cinicola BL, Piano Mortari E, Zicari AM, Agrati C, Bordoni V, Albano C, Fedele G, Schiavoni I, Leone P, Fiore S, Capponi M, Conti MG, Petrarca L, Stefanelli P, Spalice A, Midulla F, Palamara AT, Quinti I, Locatelli F, Carsetti R. Cinicola BL, et al. Front Immunol. 2022 Dec 15;13:1094727. doi: 10.3389/fimmu.2022.1094727. eCollection 2022. Front Immunol. 2022. PMID: 36591287 Free PMC article.

Although children are at low risk of severe COVID-19, the spreading of highly transmissible variants has led to increasing in COVID-19 cases and hospitalizations also in the youngest, but vaccine coverage remains low. ...We assessed the humoral and cellular immune r …

Although children are at low risk of severe COVID-19, the spreading of highly transmissible variants has led to increasing in COVID-1 …

39

COVID-19 Epidemiology, Immunity, and Vaccine Development in Children: A Review.

Fergie J, Moran MM, Cane A, Pather S, Türeci Ӧ, Srivastava A. Fergie J, et al. Vaccines (Basel). 2022 Nov 29;10(12):2039. doi: 10.3390/vaccines10122039. Vaccines (Basel). 2022. PMID: 36560448 Free PMC article. Review.

COVID-19 vaccines with available pediatric data include BNT162b2, mRNA-1273, CoronaVac, and BBIBP-CorV. Depending on age group and jurisdiction, BNT162b2 and mRNA-1273 have received full approval or emergency/conditional authorization in the United Sta …

COVID-19 vaccines with available pediatric data include BNT162b2, mRNA-1273, CoronaVac, and BBIBP-CorV. Depending on age group …

40

Effectiveness of BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and July 2022: A prospective test negative case-control study.

Chatzilena A, Hyams C, Challen R, Marlow R, King J, Adegbite D, Kinney J, Clout M, Maskell N, Oliver J, Danon L, Finn A; Avon CAP Research Group. Chatzilena A, et al. Lancet Reg Health Eur. 2022 Dec 7;25:100552. doi: 10.1016/j.lanepe.2022.100552. eCollection 2023 Feb. Lancet Reg Health Eur. 2022. PMID: 36506791 Free PMC article.

Three-dose BNT162b2 protection against hospitalisation with Omicron infection was 30.9% [5.9-49.3%], with sensitivity analyses ranging from 28.8-72.6%. ...BNT162b2 remains effective against severe SARS-CoV-2 disease. FUNDING: AvonCAP is an investigator-led project f …

Three-dose BNT162b2 protection against hospitalisation with Omicron infection was 30.9% [5.9-49.3%], with sensitivity analyses rangin …

41

BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children.

Bartsch YC, Chen JW, Kang J, Burns MD, St Denis KJ, Sheehan ML, Davis JP, Edlow AG, Balazs AB, Yonker LM, Alter G. Bartsch YC, et al. NPJ Vaccines. 2022 Dec 3;7(1):158. doi: 10.1038/s41541-022-00575-w. NPJ Vaccines. 2022. PMID: 36463314 Free PMC article.

However, the emergence of variants of concerns (VOCs) has highlighted the importance of high population-based vaccine rates to effectively suppress viral transmission and breakthrough infections. While initially left out from vaccine efforts, children have be …

However, the emergence of variants of concerns (VOCs) has highlighted the importance of high population-based vaccine rates to effect …

42

Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals.

Goh YS, Rouers A, Fong SW, Zhuo NZ, Hor PX, Loh CY, Huang Y, Neo VK, Kam IKJ, Wang B, Ngoh EZX, Salleh SNM, Lee RTC, Pada S, Sun LJ, Ong DLS, Somani J, Lee ES; NCID Study Group; COVID-19 Study Group; Maurer-Stroh S, Wang CI, Leo YS, Ren EC, Lye DC, Young BE, Ng LFP, Renia L. Goh YS, et al. Front Immunol. 2022 Nov 14;13:1031852. doi: 10.3389/fimmu.2022.1031852. eCollection 2022. Front Immunol. 2022. PMID: 36451833 Free PMC article.

The emergence of new SARS-CoV-2 variants, such as the more transmissible Delta and Omicron variants, has raised concerns on efficacy of the COVID-19 vaccines. ...However, the induced immunity by the third BNT162b2 vaccine dose was transient. The findings sugg …

The emergence of new SARS-CoV-2 variants, such as the more transmissible Delta and Omicron variants, has raised concerns on efficacy …

43

Analyses of reported severe adverse events after immunization with SARS-CoV-2 vaccines in the United States: One year on.

Mangat HS, Musah A, Luedtke S, Syed AA, Maramattom BV, Maruthanal J, Bosman A, Kostkova P. Mangat HS, et al. Front Public Health. 2022 Oct 13;10:972464. doi: 10.3389/fpubh.2022.972464. eCollection 2022. Front Public Health. 2022. PMID: 36311588 Free PMC article.

All sAEFI in conjunction with mRNA (BNT-162b2 or mRNA-1273) or adenovector (Ad26.COV2.S) vaccines were included. The 28-day crude cumulative rates for reported emergency department (ED) visits and sAEFI viz. hospitalizations, life-threatening events and deaths follo …

All sAEFI in conjunction with mRNA (BNT-162b2 or mRNA-1273) or adenovector (Ad26.COV2.S) vaccines were included. The 28-day cr …

44

Coronavirus (COVID-19) Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) (Archived).

Aleem A, Nadeem AJ. Aleem A, et al. 2022 Oct 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2022 Oct 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 34033367 Free Books & Documents.

The BNT162b2, mRNA-1273 have been approved by the U.S. FDA and the Ad26.COV2.S has received Emergency Use Authorization. ...The BNT162b2 and mRNA-1273 vaccines are both mRNA-based, while the Ad26.COV2. S and ChAdOx1 nCoV-19 vaccines incorporate …

The BNT162b2, mRNA-1273 have been approved by the U.S. FDA and the Ad26.COV2.S has received Emergency Use Authorization. ...Th …

45

mRNA vaccination drives differential mucosal neutralizing antibody profiles in naive and SARS-CoV-2 previously-infected individuals.

Longet S, Hargreaves A, Healy S, Brown R, Hornsby HR, Meardon N, Tipton T, Barnes E, Dunachie S, Duncan CJA, Klenerman P, Richter A, Turtle L, de Silva TI, Carroll MW. Longet S, et al. Front Immunol. 2022 Sep 8;13:953949. doi: 10.3389/fimmu.2022.953949. eCollection 2022. Front Immunol. 2022. PMID: 36159846 Free PMC article.

Two doses of BNT162b2 mRNA vaccine induces a strong systemic SARS-CoV-2 specific humoral response. However, SARS-CoV-2 airborne transmission makes mucosal immune response a crucial first line of defense. ...Additionally, we investigated the impact of h …

Two doses of BNT162b2 mRNA vaccine induces a strong systemic SARS-CoV-2 specific humoral response. However, SARS-CoV-2 …

46

Antibody Response against Circulating Omicron Variants 8 Months after the Third Dose of mRNA Vaccine.

Anichini G, Terrosi C, Gori Savellini G, Gandolfo C, Barbagli F, Carta GA, Fabrizi S, Miceli GB, Cusi MG. Anichini G, et al. Vaccines (Basel). 2022 Sep 10;10(9):1512. doi: 10.3390/vaccines10091512. Vaccines (Basel). 2022. PMID: 36146590 Free PMC article.

The COVID-19 wave is being recently propelled by BA.2 and, particularly, BA.5 lineages, showing clear transmission advantages over the previously circulating strains. In this study, neutralizing antibody responses against SARS-CoV-2 Wild-Type, BA.2 and BA.5 Omicron subline …

The COVID-19 wave is being recently propelled by BA.2 and, particularly, BA.5 lineages, showing clear transmission advantages over th …

47

Public health impact of booster vaccination against COVID-19 in the UK during Delta variant dominance in autumn 2021.

Mendes D, Chapman R, Gal P, Atwell J, Nguyen JL, Hamson L, Di Fusco M, Czudek C, Yang J. Mendes D, et al. J Med Econ. 2022 Jan-Dec;25(1):1039-1050. doi: 10.1080/13696998.2022.2111935. J Med Econ. 2022. PMID: 36097853 Free article.

48

Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.

Neerukonda SN, Wang R, Vassell R, Baha H, Lusvarghi S, Liu S, Wang T, Weiss CD, Wang W. Neerukonda SN, et al. J Virol. 2022 Sep 14;96(17):e0114022. doi: 10.1128/jvi.01140-22. Epub 2022 Aug 24. J Virol. 2022. PMID: 36000843 Free PMC article.

Finally, neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7- to 8-fold less potent than the D614G. These results provide insights into the transmissibility and immune evasion capacity of th …

Finally, neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine wa …

49

Immunogenicity of SARS-CoV-2 vaccines in patients with cancer.

Kakkassery H, Carpenter E, Patten PEM, Irshad S. Kakkassery H, et al. Trends Mol Med. 2022 Dec;28(12):1082-1099. doi: 10.1016/j.molmed.2022.07.006. Epub 2022 Aug 3. Trends Mol Med. 2022. PMID: 35999131 Free PMC article. Review.

Transmission of the SARS-CoV-2 virus and its corresponding disease (COVID-19) has been shown to impose a higher burden on cancer patients than on the general population. Approved vaccines for use include new technology mRNA vaccines such as BNT162b2 (Pfizer-B …

Transmission of the SARS-CoV-2 virus and its corresponding disease (COVID-19) has been shown to impose a higher burden on cancer pati …

50

Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy).

Isgrò MA, Trillò G, Russo L, Tornesello AL, Buonaguro L, Tornesello ML, Miscio L, Normanno N, Bianchi AAM, Buonaguro FM, Cavalcanti E; anti-COVID-19 INT Task Force. Isgrò MA, et al. Infect Agent Cancer. 2022 Jul 28;17(1):40. doi: 10.1186/s13027-022-00451-1. Infect Agent Cancer. 2022. PMID: 35902961 Free PMC article.

BACKGROUND: Both SARS-CoV-2 mRNA-based vaccines [BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna)] have shown high efficacy, with very modest side effects in limiting transmission of SARS-CoV-2 and in preventing the severe COVID-19 disease, character …

BACKGROUND: Both SARS-CoV-2 mRNA-based vaccines [BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna)] have shown high ef …

51

COVID-19 Outbreak and BNT162b2 mRNA Vaccination Coverage in a Correctional Facility during Circulation of the SARS-CoV-2 Omicron BA.1 Variant in Italy.

Stufano A, Buonvino N, Trombetta CM, Pontrelli D, Marchi S, Lobefaro G, De Benedictis L, Lorusso E, Carofiglio MT, Vasinioti VI, Montomoli E, Decaro N, Lovreglio P. Stufano A, et al. Vaccines (Basel). 2022 Jul 17;10(7):1137. doi: 10.3390/vaccines10071137. Vaccines (Basel). 2022. PMID: 35891301 Free PMC article.

The recent spread of the highly mutated SARS-CoV-2 Omicron variant (B.1.1.529) has raised concerns about protection against COVID-19 in congregate settings such as prisons, characterized by a high risk of transmission and possible difficulties in obtaining adequate vaccina …

The recent spread of the highly mutated SARS-CoV-2 Omicron variant (B.1.1.529) has raised concerns about protection against COVID-19 in cong …

52

Vaccine mRNA Can Be Detected in Blood at 15 Days Post-Vaccination.

Fertig TE, Chitoiu L, Marta DS, Ionescu VS, Cismasiu VB, Radu E, Angheluta G, Dobre M, Serbanescu A, Hinescu ME, Gherghiceanu M. Fertig TE, et al. Biomedicines. 2022 Jun 28;10(7):1538. doi: 10.3390/biomedicines10071538. Biomedicines. 2022. PMID: 35884842 Free PMC article.

We found that vaccine-associated synthetic mRNA persists in systemic circulation for at least 2 weeks. Furthermore, we used transmission electron microscopy (TEM) to investigate SARS-CoV-2 spike protein expression in human leukemic cells and in primary mononu …

We found that vaccine-associated synthetic mRNA persists in systemic circulation for at least 2 weeks. Furthermore, we used …

53

Third COVID-19 vaccine dose boosts neutralizing antibodies in poor responders.

Lake DF, Roeder AJ, Gonzalez-Moa MJ, Koehler M, Kaleta E, Jasbi P, Vanderhoof J, McKechnie D, Forman J, Edwards BA, Seit-Nebi A, Svarovsky S. Lake DF, et al. Commun Med (Lond). 2022 Jul 11;2:85. doi: 10.1038/s43856-022-00151-2. eCollection 2022. Commun Med (Lond). 2022. PMID: 35832309 Free PMC article.

BACKGROUND: While evaluating COVID-19 vaccine responses using a rapid neutralizing antibody (NAb) test, we observed that 25% of mRNA vaccine recipients did not neutralize >50%. ...METHODS: 269 healthy individuals ranging in age from 19 to 80 (Average age = …

BACKGROUND: While evaluating COVID-19 vaccine responses using a rapid neutralizing antibody (NAb) test, we observed that 25% of mR …

54

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway.

Willett BJ, Grove J, MacLean OA, Wilkie C, De Lorenzo G, Furnon W, Cantoni D, Scott S, Logan N, Ashraf S, Manali M, Szemiel A, Cowton V, Vink E, Harvey WT, Davis C, Asamaphan P, Smollett K, Tong L, Orton R, Hughes J, Holland P, Silva V, Pascall DJ, Puxty K, da Silva Filipe A, Yebra G, Shaaban S, Holden MTG, Pinto RM, Gunson R, Templeton K, Murcia PR, Patel AH, Klenerman P, Dunachie S; PITCH Consortium; COVID-19 Genomics UK (COG-UK) Consortium; Haughney J, Robertson DL, Palmarini M, Ray S, Thomson EC. Willett BJ, et al. Nat Microbiol. 2022 Aug;7(8):1161-1179. doi: 10.1038/s41564-022-01143-7. Epub 2022 Jul 7. Nat Microbiol. 2022. PMID: 35798890 Free PMC article.

The emergence of hypermutated, increasingly transmissible variants of concern (VOCs) threaten this strategy. Omicron (B.1.1.529), the fifth VOC to be described, harbours multiple amino acid mutations in spike, half of which lie within the receptor-binding domain. Here we d …

The emergence of hypermutated, increasingly transmissible variants of concern (VOCs) threaten this strategy. Omicron (B.1.1.529), the …

55

Estimated Number of COVID-19 Infections, Hospitalizations, and Deaths Prevented Among Vaccinated Persons in the US, December 2020 to September 2021.

Steele MK, Couture A, Reed C, Iuliano D, Whitaker M, Fast H, Hall AJ, MacNeil A, Cadwell B, Marks KJ, Silk BJ. Steele MK, et al. JAMA Netw Open. 2022 Jul 1;5(7):e2220385. doi: 10.1001/jamanetworkopen.2022.20385. JAMA Netw Open. 2022. PMID: 35793085 Free PMC article.

IMPORTANCE: The number of SARS-CoV-2 infections and COVID-19-associated hospitalizations and deaths prevented among vaccinated persons, independent of the effect of reduced transmission, is a key measure of vaccine impact. OBJECTIVE: To estimate the number of SARS-C …

IMPORTANCE: The number of SARS-CoV-2 infections and COVID-19-associated hospitalizations and deaths prevented among vaccinated persons, inde …

56

COVID-19 booster vaccine attitudes and behaviors among university students and staff in the United States: The USC Trojan pandemic research Initiative.

Lee RC, Hu H, Kawaguchi ES, Kim AE, Soto DW, Shanker K, Klausner JD, Van Orman S, Unger JB. Lee RC, et al. Prev Med Rep. 2022 Aug;28:101866. doi: 10.1016/j.pmedr.2022.101866. Epub 2022 Jun 27. Prev Med Rep. 2022. PMID: 35785408 Free PMC article.

Although authorized mRNA COVID-19 vaccines (BNT162b2 by BioNTech/Pfizer and mRNA-1273 by Moderna) significantly reduce morbidity and mortality, recent evidence suggests that immunity wanes over time, and that a booster dose could further reduce COVID-19 tr …

Although authorized mRNA COVID-19 vaccines (BNT162b2 by BioNTech/Pfizer and mRNA-1273 by Moderna) significantly reduce …

57

Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 - 21 years old: A Systematic Review and Meta-analysis.

Sadeghi S, Kalantari Y, Shokri S, Fallahpour M, Nafissi N, Goodarzi A, Valizadeh R. Sadeghi S, et al. J Clin Virol. 2022 Aug;153:105196. doi: 10.1016/j.jcv.2022.105196. Epub 2022 Jun 3. J Clin Virol. 2022. PMID: 35716417 Free PMC article.

Data were collected about multiple vaccines including BNT162b2 (Pfizer), mRNA-1273 (Moderna), JNJ-78436735 (Johnson and Johnson), CoronaVac (Sinovac), BBIBP-CorV (Sinopharm), adenovirus type-5-vectored vaccine, ZyCov-D, and BBV152 (COVAXIN). ...Meanwhile, ove …

Data were collected about multiple vaccines including BNT162b2 (Pfizer), mRNA-1273 (Moderna), JNJ-78436735 (Johnson and Johnso …

58

Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients - implications for the omicron variant.

Peled Y, Afek A, Kreiss Y, Rahav G, Nemet I, Kliker L, Indenbaum V, Ram E, Lavee J, Segev A, Matezki S, Sternik L, Raanani E, Lustig Y, Patel JK, Mandelboim M. Peled Y, et al. J Heart Lung Transplant. 2022 Oct;41(10):1417-1425. doi: 10.1016/j.healun.2022.05.014. Epub 2022 May 24. J Heart Lung Transplant. 2022. PMID: 35710484 Free PMC article.

BACKGROUND: The durability of the immune response following the 3-dose BNT162b2 vaccination is unknown. The complexity of the situation is enhanced by the threat that highly transmissible variants may further accelerate the decline in the protection afforded by m …

BACKGROUND: The durability of the immune response following the 3-dose BNT162b2 vaccination is unknown. The complexity of the situati …

59

Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure.

Reynolds CJ, Pade C, Gibbons JM, Otter AD, Lin KM, Muñoz Sandoval D, Pieper FP, Butler DK, Liu S, Joy G, Forooghi N, Treibel TA, Manisty C, Moon JC; COVIDsortium Investigators§; COVIDsortium Immune Correlates Network§; Semper A, Brooks T, McKnight Á, Altmann DM, Boyton RJ, Abbass H, Abiodun A, Alfarih M, Alldis Z, Altmann DM, Amin OE, Andiapen M, Artico J, Augusto JB, Baca GL, Bailey SNL, Bhuva AN, Boulter A, Bowles R, Boyton RJ, Bracken OV, O'Brien B, Brooks T, Bullock N, Butler DK, Captur G, Carr O, Champion N, Chan C, Chandran A, Coleman T, Couto de Sousa J, Couto-Parada X, Cross E, Cutino-Moguel T, D'Arcangelo S, Davies RH, Douglas B, Di Genova C, Dieobi-Anene K, Diniz MO, Ellis A, Feehan K, Finlay M, Fontana M, Forooghi N, Francis S, Gibbons JM, Gillespie D, Gilroy D, Hamblin M, Harker G, Hemingway G, Hewson J, Heywood W, Hickling LM, Hicks B, Hingorani AD, Howes L, Itua I, Jardim V, Lee WJ, Jensen M, Jones J, Jones M, Joy G, Kapil V, Kelly C, Kurdi H, Lambourne J, Lin KM, Liu S, Lloyd A, Louth S, Maini MK, Mandadapu V, Manisty C, McKnight Á, Menacho K, Mfuko C, Mills K, Millward S, Mitchelmore O, Moon C, Moon J, Muñoz Sandoval D, Murray SM, Noursadeghi M, Otter A, Pade C, Pa… See abstract for full author list ➔ Reynolds CJ, et al. Science. 2022 Jul 15;377(6603):eabq1841. doi: 10.1126/science.abq1841. Epub 2022 Jul 15. Science. 2022. PMID: 35699621 Free PMC article.

The Omicron, or Pango lineage B.1.1.529, variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) carries multiple spike mutations with high transmissibility and partial neutralizing antibody (nAb) escape. Vaccinated individuals show protection against sever …

The Omicron, or Pango lineage B.1.1.529, variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) carries multiple spike muta …

60

A 2-month field cohort study of SARS-CoV-2 in saliva of BNT162b2 vaccinated nursing home workers.

Saegerman C, Diep AN, Renault V, Donneau AF, Stamatakis L, Coppieters W, Michel F, Breuer C, Dandoy M, Ek O, Gourzones C, Schyns J, Goffin E, Minner F, Durkin K, Artesi M, Bours V, Bureau F, Gillet L. Saegerman C, et al. Commun Med (Lond). 2022 Jan 10;2:1. doi: 10.1038/s43856-021-00067-3. eCollection 2022. Commun Med (Lond). 2022. PMID: 35603280 Free PMC article.

Three groups of workers, i.e., non-vaccinated (n = 1618), one-dosed vaccinated (n = 1454), and two-dosed vaccinated (n = 2379) of BNT162b2 mRNA COVID-19 vaccine, were followed-up weekly. Their saliva samples were used to monitor the shedding of SARS-CoV-2. .. …

Three groups of workers, i.e., non-vaccinated (n = 1618), one-dosed vaccinated (n = 1454), and two-dosed vaccinated (n = 2379) of BNT162b …

61

High coverage COVID-19 mRNA vaccination rapidly controls SARS-CoV-2 transmission in long-term care facilities.

De Salazar PM, Link NB, Lamarca K, Santillana M. De Salazar PM, et al. Commun Med (Lond). 2021 Jul 16;1:16. doi: 10.1038/s43856-021-00015-1. eCollection 2021. Commun Med (Lond). 2021. PMID: 35602197 Free PMC article.

METHODS: We evaluate the early effect of the administration of BNT162b2-mRNA vaccine to individuals older than 64 years residing in LTCFs in Catalonia, Spain. ...CONCLUSIONS: Our findings provide evidence that high-coverage vaccination is the most effective i …

METHODS: We evaluate the early effect of the administration of BNT162b2-mRNA vaccine to individuals older than 64 years …

62

How long-term metal and lead exposure among foundry workers affect COVID-19 infection outcomes in Jordan.

Saadh M. Saadh M. Environ Sci Pollut Res Int. 2022 Oct;29(46):70408-70412. doi: 10.1007/s11356-022-20845-3. Epub 2022 May 19. Environ Sci Pollut Res Int. 2022. PMID: 35589897 Free PMC article.

This study aims to evaluated thyroid functions, glutathione level, and the risk of infection with SARS-CoV-2 after vaccinated (two doses of the BNT162b2 mRNA COVID-19 vaccine) foundry workers in Jordan. We examined the efficacy BNT162b2 vaccine …

This study aims to evaluated thyroid functions, glutathione level, and the risk of infection with SARS-CoV-2 after vaccinated (two doses of …

63

Assessment of Neonatal Cord Blood SARS-CoV-2 Antibodies after COVID-19 Vaccination in Pregnancy: A Prospective Cohort Study.

Sourouni M, Braun J, Oelmeier K, Möllers M, Willy D, Hennies MT, Köster HA, Pecks U, Klockenbusch W, Schmitz R. Sourouni M, et al. Geburtshilfe Frauenheilkd. 2022 May 6;82(5):510-516. doi: 10.1055/a-1721-4908. eCollection 2022 May. Geburtshilfe Frauenheilkd. 2022. PMID: 35528187 Free PMC article.

So far, limited data has shown transplacental transmission of antibodies after coronavirus disease 2019 (COVID-19) vaccination with BNT162b2 in the third trimester. Our aim was to detect vertically transferred immunity after COVID-19 vaccination with BNT162b2 …

So far, limited data has shown transplacental transmission of antibodies after coronavirus disease 2019 (COVID-19) vaccination with …

64

Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022.

Prasad N, Derado G, Nanduri SA, Reses HE, Dubendris H, Wong E, Soe MM, Li Q, Dollard P, Bagchi S, Edwards J, Shang N, Budnitz D, Bell J, Verani JR, Benin A, Link-Gelles R, Jernigan J, Pilishvili T. Prasad N, et al. MMWR Morb Mortal Wkly Rep. 2022 May 6;71(18):633-637. doi: 10.15585/mmwr.mm7118a4. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35511708 Free PMC article.

Nursing home residents have experienced disproportionally high levels of COVID-19-associated morbidity and mortality and were prioritized for early COVID-19 vaccination (1). Following reported declines in vaccine-induced immunity after primary series vaccination, defined a …

Nursing home residents have experienced disproportionally high levels of COVID-19-associated morbidity and mortality and were prioritized fo …

65

BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19.

Kaznadzey A, Tutukina M, Bessonova T, Kireeva M, Mazo I. Kaznadzey A, et al. Front Immunol. 2022 Apr 13;13:797918. doi: 10.3389/fimmu.2022.797918. eCollection 2022. Front Immunol. 2022. PMID: 35493476 Free PMC article.

Here we analyzed the levels of IgG antibodies against the receptor-binding domain (RBD) of the viral spike protein after the administration of three types of popular vaccines, BNT162b2, mRNA-1273, or Sputnik V, using the same ELISA assay to compare their effects. .. …

Here we analyzed the levels of IgG antibodies against the receptor-binding domain (RBD) of the viral spike protein after the administration …

66

Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine.

Agrati C, Castilletti C, Goletti D, Sacchi A, Bordoni V, Mariotti D, Notari S, Matusali G, Meschi S, Petrone L, Aiello A, Najafi Fard S, Farroni C, Colavita F, Lapa D, Leone S, Agresta A, Capobianchi M, Ippolito G, Vaia F, Puro V; INMI COVID-19 Vaccine Study Group. Agrati C, et al. Sci Rep. 2022 Apr 23;12(1):6687. doi: 10.1038/s41598-022-07741-z. Sci Rep. 2022. PMID: 35461335 Free PMC article.

Vaccine is the main public health measure to reduce SARS-CoV-2 transmission and hospitalization, and a massive scientific effort worldwide resulted in the rapid development of effective vaccines. ...BNT162b2-mRNA vaccine induced both humoral and …

Vaccine is the main public health measure to reduce SARS-CoV-2 transmission and hospitalization, and a massive scientific effo …

67

Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021.

Braeye T, Catteau L, Brondeel R, van Loenhout JAF, Proesmans K, Cornelissen L, Van Oyen H, Stouten V, Hubin P, Billuart M, Djiena A, Mahieu R, Hammami N, Van Cauteren D, Wyndham-Thomas C. Braeye T, et al. Vaccine. 2022 May 11;40(22):3027-3037. doi: 10.1016/j.vaccine.2022.04.025. Epub 2022 Apr 12. Vaccine. 2022. PMID: 35459558 Free PMC article.

METHODS: We estimated VE against transmission of infection (VET) from Belgian contact tracing data for high-risk exposure contacts between 26/01/2021 and 14/12/2021 by susceptibility (VEs) and infectiousness of breakthrough cases (VEi) for a complete schedule of Ad26.COV2. …

METHODS: We estimated VE against transmission of infection (VET) from Belgian contact tracing data for high-risk exposure contacts be …

68

mRNA- and Adenovirus-Based Vaccines against SARS-CoV-2 in HIV-Positive People.

Garbuglia AR, Minosse C, Del Porto P. Garbuglia AR, et al. Viruses. 2022 Apr 1;14(4):748. doi: 10.3390/v14040748. Viruses. 2022. PMID: 35458478 Free PMC article. Review.

Among these, mRNA- (BNT162b2 and mRNA1273) and adenovirus-based (ChAdOx1) vaccines were developed through the use of novel technologies. ...In this review, we provide a description of the characteristics of mRNA- and adenovirus-based vaccines and of the immun …

Among these, mRNA- (BNT162b2 and mRNA1273) and adenovirus-based (ChAdOx1) vaccines were developed through the use of novel tec …

69

The Dynamics of Changes in the Concentration of IgG against the S1 Subunit in Polish Healthcare Workers in the Period from 1 to 12 Months after Injection, Including Four COVID-19 Vaccines.

Skorupa M, Szczepanek J, Goroncy A, Jarkiewicz-Tretyn J, Ptaszyńska B, Rajewski P, Koper W, Pałgan K, Tretyn A. Skorupa M, et al. Vaccines (Basel). 2022 Mar 24;10(4):506. doi: 10.3390/vaccines10040506. Vaccines (Basel). 2022. PMID: 35455255 Free PMC article.

CONCLUSION: The cut-off date for protection against the disease seems to be the period 8-9 months from the vaccination for mRNA vaccines and 5-6 months for vector vaccines. The introduction of a booster dose was the right decision, which could have a real impact on restric …

CONCLUSION: The cut-off date for protection against the disease seems to be the period 8-9 months from the vaccination for mRNA vacci …

70

Effectiveness of mRNA BNT162b2 COVID-19 vaccine against SARS-CoV-2 Delta variant among elderly residents from a long-term care facility, South of France, May 2021.

Sánchez Ruiz MA, Adonias G, Robaglia-Schlupp A, Rapilly F, Chabert M, Ramalli L, Reilhes O, Bruel C, Malfait P, Chaud P. Sánchez Ruiz MA, et al. Eur Rev Med Pharmacol Sci. 2022 Apr;26(7):2586-2591. doi: 10.26355/eurrev_202204_28496. Eur Rev Med Pharmacol Sci. 2022. PMID: 35442474 Free article.

We assessed the vaccine effectiveness (VE) of mRNA BNT162b2 (BioNTech-Pfizer) against SARS-CoV-2 Delta variant during an outbreak affecting long-term care facility (LTCF) residents in southern France, May 2021. ...CONCLUSIONS: We found a high BNT162b2 …

We assessed the vaccine effectiveness (VE) of mRNA BNT162b2 (BioNTech-Pfizer) against SARS-CoV-2 Delta variant during a …

71

US Severe Acute Respiratory Syndrome Coronavirus 2 Epsilon Variant: Highly Transmissible but With an Adjusted Muted Host T-Cell Response.

Plummer JT, Contreras D, Zhang W, Binek A, Zhang R, Dezem F, Chen SS, Davis BD, Sincuir Martinez J, Stotland A, Kreimer S, Makhoul E, Heneidi S, Eno C, Shin B, Berg AH, Cheng S; CORALE Study Group; Jordan SC, Vail E, Van Eyk JE, Morgan MA. Plummer JT, et al. Clin Infect Dis. 2022 Nov 30;75(11):1940-1949. doi: 10.1093/cid/ciac295. Clin Infect Dis. 2022. PMID: 35438777 Free PMC article.

Importantly, this paired transcriptomics and proteomic profiling of host cellular response to live virus revealed an altered leukocyte response and metabolic messenger RNA processing with the epsilon variant. To ascertain host response to SARS-CoV-2 infection, prima …

Importantly, this paired transcriptomics and proteomic profiling of host cellular response to live virus revealed an altered leukocyte respo …

72

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.

Liu X, Munro APS, Feng S, Janani L, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dejnirattisai W, Dodd K, Enever Y, Qureshi E, Goodman AL, Green CA, Harndahl L, Haughney J, Hicks A, van der Klaauw AA, Kwok J, Libri V, Llewelyn MJ, McGregor AC, Minassian AM, Moore P, Mughal M, Mujadidi YF, Holliday K, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Serafimova T, Saralaya D, Screaton GR, Sharma S, Sheridan R, Sturdy A, Supasa P, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Lambe T, Nguyen-Van-Tam JS, Cornelius V, Snape MD, Faust SN; COV-BOOST study group. Liu X, et al. J Infect. 2022 Jun;84(6):795-813. doi: 10.1016/j.jinf.2022.04.018. Epub 2022 Apr 9. J Infect. 2022. PMID: 35405168 Free PMC article. Clinical Trial.

The decay rate of cellular responses were similar between all the vaccine schedules and doses. CONCLUSIONS: 84 days after a third dose of COVID-19 vaccine the decay rates of humoral response were different between vaccines. ...Policymakers may also consider adenovir …

The decay rate of cellular responses were similar between all the vaccine schedules and doses. CONCLUSIONS: 84 days after a third dos …

73

Specific Anti-SARS-CoV-2 Humoral and Cellular Immune Responses After Booster Dose of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine: Integrated Study of Adaptive Immune System Components.

Busà R, Sorrentino MC, Russelli G, Amico G, Miceli V, Miele M, Di Bella M, Timoneri F, Gallo A, Zito G, Di Carlo D, Conaldi PG, Bulati M. Busà R, et al. Front Immunol. 2022 Mar 24;13:856657. doi: 10.3389/fimmu.2022.856657. eCollection 2022. Front Immunol. 2022. PMID: 35401503 Free PMC article.

The aim of this work has been to investigate the effects of BNT162b2 Pfizer-BioNTech mRNA-based vaccine booster dose in a cohort of 11 uninfected immunocompetent (ICs), evaluating the humoral and cellular responses, with more carefulness on memory B and T cel …

The aim of this work has been to investigate the effects of BNT162b2 Pfizer-BioNTech mRNA-based vaccine booster dose in …

74

Why COVID vaccines for young children (5-11 years) are not essential at this moment in time?

Merchant HA. Merchant HA. J Pharm Policy Pract. 2022 Mar 28;15(1):25. doi: 10.1186/s40545-022-00424-0. J Pharm Policy Pract. 2022. PMID: 35346387 Free PMC article.

The article explains why we should not rush mass-immunising young children and a delayed immunisation can be beneficial in offering a more suitable vaccine formulation for children, such as the nasal COVID vaccine, that is going to be available soon and will provide …

The article explains why we should not rush mass-immunising young children and a delayed immunisation can be beneficial in offering a more s …

75

Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination and Pediatric Age on Delta Variant Household Transmission.

Ng OT, Koh V, Chiew CJ, Marimuthu K, Thevasagayam NM, Mak TM, Chua JK, Ong SSH, Lim YK, Ferdous Z, Johari AKB, Cui L, Lin RTP, Tan KB, Cook AR, Leo YS, Lee VJM. Ng OT, et al. Clin Infect Dis. 2022 Aug 24;75(1):e35-e43. doi: 10.1093/cid/ciac219. Clin Infect Dis. 2022. PMID: 35323887 Free PMC article.

RESULTS: Among 8470 Delta variant-exposed contacts linked to 2583 indices, full-vaccination of the index with BNT162b2 or mRNA-1273 was associated with reduction in acquisition by contacts (adjusted odds ratio [aOR], 0.56; 95% robust confidence interval [RCI], .44-. …

RESULTS: Among 8470 Delta variant-exposed contacts linked to 2583 indices, full-vaccination of the index with BNT162b2 or mRNA …

76

Gauging the Impact of Artificial Intelligence and Mathematical Modeling in Response to the COVID-19 Pandemic: A Systematic Review.

Hassan A, Prasad D, Rani S, Alhassan M. Hassan A, et al. Biomed Res Int. 2022 Mar 14;2022:7731618. doi: 10.1155/2022/7731618. eCollection 2022. Biomed Res Int. 2022. Retraction in: Biomed Res Int. 2023 Dec 29;2023:9819728. doi: 10.1155/2023/9819728 PMID: 35309167 Free PMC article. Retracted.

The study also considered the impact of Pfizer-BioNTech (BNT162b2), AstraZeneca (ChAd0x1), and Moderna (mRNA-1273) on Beta (B.1.1.7) and Delta (B.1.617.2) viral variants and the impact of administering booster doses given the evolution of viral variants of the virus …

The study also considered the impact of Pfizer-BioNTech (BNT162b2), AstraZeneca (ChAd0x1), and Moderna (mRNA-1273) on Beta (B. …

77

Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.

Jalkanen P, Kolehmainen P, Haveri A, Huttunen M, Laine L, Österlund P, Tähtinen PA, Ivaska L, Maljanen S, Reinholm A, Belik M, Smura T, Häkkinen HK, Ortamo E, Kantele A, Julkunen I, Lempainen J, Kakkola L. Jalkanen P, et al. Microbiol Spectr. 2022 Apr 27;10(2):e0225221. doi: 10.1128/spectrum.02252-21. Epub 2022 Mar 9. Microbiol Spectr. 2022. PMID: 35262410 Free PMC article.

To analyze the dynamics of COVID-19 mRNA vaccine-induced antibody responses, we followed 52 health care workers in Finland for 6 months after receiving two doses of BNT162b2 vaccine with a 3-week interval. ...Our data show that after 6 months post two …

To analyze the dynamics of COVID-19 mRNA vaccine-induced antibody responses, we followed 52 health care workers in Finland for …

78

Early Flare-Ups of Myasthenia Gravis After Thoracoscopic Thymectomy in a Patient Recently Receiving BNT162b2 mRNA COVID-19 Vaccination.

Dharmasaroja P. Dharmasaroja P. Cureus. 2022 Jan 24;14(1):e21571. doi: 10.7759/cureus.21571. eCollection 2022 Jan. Cureus. 2022. PMID: 35228930 Free PMC article.

Myasthenia gravis (MG) is an autoimmune disorder characterized by abnormal neuromuscular transmission. The thymus is believed to play a key role in the pathogenesis of MG, and thymectomy has been an optional treatment for the disease. ...A 31-year-old female received the s …

Myasthenia gravis (MG) is an autoimmune disorder characterized by abnormal neuromuscular transmission. The thymus is believed to play …

79

Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence.

Focosi D, Maggi F, Casadevall A. Focosi D, et al. Viruses. 2022 Jan 19;14(2):187. doi: 10.3390/v14020187. Viruses. 2022. PMID: 35215783 Free PMC article. Review.

Systemic vaccination by intramuscular delivery induces no or low-titer neutralizing IgA against vaccine antigens. Mucosal priming or boosting, is needed to provide sterilizing immunity. On the other side of the coin, sterilizing immunity, by zeroing interhuman transmiss …

Systemic vaccination by intramuscular delivery induces no or low-titer neutralizing IgA against vaccine antigens. Mucosal priming or …

80

Effectiveness of Vaccination against SARS-CoV-2 Infection in the Pre-Delta Era: A Systematic Review and Meta-Analysis.

Meggiolaro A, Sane Schepisi M, Nikolaidis GF, Mipatrini D, Siddu A, Rezza G. Meggiolaro A, et al. Vaccines (Basel). 2022 Jan 21;10(2):157. doi: 10.3390/vaccines10020157. Vaccines (Basel). 2022. PMID: 35214615 Free PMC article. Review.

(1) Background: The objective of this study was to assess the effectiveness of SARS-CoV-2 vaccines in terms of prevention of disease and transmission in the pre-Delta era. The evaluation was narrowed to two mRNA vaccines and two modified adenovirus-vectored vaccines …

(1) Background: The objective of this study was to assess the effectiveness of SARS-CoV-2 vaccines in terms of prevention of disease and …

81

Extensive Cerebral Venous Sinus Thrombosis (CVST) After the First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine without Thrombotic Thrombocytopenia Syndrome (TTS) in a Healthy Woman.

Alhashim A, Hadhiah K, Al Khalifah Z, Alhaddad FM, Al ARhain SA, Bin Saif FH, Abid A, Al Gamdi O, Alsulaiman F, AlQarni M. Alhashim A, et al. Am J Case Rep. 2022 Feb 9;23:e934744. doi: 10.12659/AJCR.934744. Am J Case Rep. 2022. PMID: 35136010 Free PMC article.

BACKGROUND COVID-19 is an acute respiratory disease caused by the SARS-CoV-2 virus, which was discovered in 2019. The high transmission and seriousness of COVID-19 necessitated the development of an effective vaccine to control spread of the disease. ...CASE REPORT …

BACKGROUND COVID-19 is an acute respiratory disease caused by the SARS-CoV-2 virus, which was discovered in 2019. The high transmission …

82

BNT162b2 mRNA COVID-19 (Comirnaty) Vaccine Effectiveness in Elderly Patients Who Live in Long-Term Care Facilities: A Nationwide Cohort.

Goldin S, Adler L, Azuri J, Mendel L, Haviv S, Maimon N. Goldin S, et al. Gerontology. 2022;68(12):1350-1357. doi: 10.1159/000521899. Epub 2022 Feb 8. Gerontology. 2022. PMID: 35134810 Free PMC article.

This study aimed to estimate the effectiveness of the BNT162b2 mRNA COVID-19 (Comirnaty) vaccine in reducing COVID-19 morbidity and mortality in LTCF residents. ...CONCLUSION: This study shows that the BNT162b2 mRNA COVID-19 vaccine effec …

This study aimed to estimate the effectiveness of the BNT162b2 mRNA COVID-19 (Comirnaty) vaccine in reducing COVID-19 m …

83

Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario.

Nasreen S, Chung H, He S, Brown KA, Gubbay JB, Buchan SA, Fell DB, Austin PC, Schwartz KL, Sundaram ME, Calzavara A, Chen B, Tadrous M, Wilson K, Wilson SE, Kwong JC; Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators. Nasreen S, et al. Nat Microbiol. 2022 Mar;7(3):379-385. doi: 10.1038/s41564-021-01053-0. Epub 2022 Feb 7. Nat Microbiol. 2022. PMID: 35132198

SARS-CoV-2 variants of concern (VOC) are more transmissible and may have the potential for increased disease severity and decreased vaccine effectiveness. We estimated the effectiveness of BNT162b2 (Pfizer-BioNTech Comirnaty), mRNA-1273 (Moderna Spikev …

SARS-CoV-2 variants of concern (VOC) are more transmissible and may have the potential for increased disease severity and decreased …

84

Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections.

Abu-Raddad LJ, Chemaitelly H, Ayoub HH, Tang P, Coyle P, Hasan MR, Yassine HM, Benslimane FM, Al-Khatib HA, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Khal A, Al-Thani MH, Bertollini R. Abu-Raddad LJ, et al. Nat Commun. 2022 Jan 27;13(1):532. doi: 10.1038/s41467-022-28199-7. Nat Commun. 2022. PMID: 35087035 Free PMC article.

Here, we investigate differences in RT-qPCR Ct values across Qatar's national cohorts of primary infections, reinfections, BNT162b2 (Pfizer-BioNTech) breakthrough infections, and mRNA-1273 (Moderna) breakthrough infections. ...The Ct value is 1.3 (95% CI: 0.9-1.8) c …

Here, we investigate differences in RT-qPCR Ct values across Qatar's national cohorts of primary infections, reinfections, BNT162b2 ( …

85

Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel.

Prunas O, Warren JL, Crawford FW, Gazit S, Patalon T, Weinberger DM, Pitzer VE. Prunas O, et al. Science. 2022 Mar 11;375(6585):1151-1154. doi: 10.1126/science.abl4292. Epub 2022 Jan 27. Science. 2022. PMID: 35084937 Free PMC article.

The effectiveness of vaccines against COVID-19 on the individual level is well established. However, few studies have examined vaccine effectiveness against transmission. We used a chain binomial model to estimate the effectiveness of vaccination with BNT162b2 …

The effectiveness of vaccines against COVID-19 on the individual level is well established. However, few studies have examined vaccine …

86

The Burden of COVID-19 in Children and Its Prevention by Vaccination: A Joint Statement of the Israeli Pediatric Association and the Israeli Society for Pediatric Infectious Diseases.

Stein M, Ashkenazi-Hoffnung L, Greenberg D, Dalal I, Livni G, Chapnick G, Stein-Zamir C, Ashkenazi S, Hecht-Sagie L, Grossman Z. Stein M, et al. Vaccines (Basel). 2022 Jan 6;10(1):81. doi: 10.3390/vaccines10010081. Vaccines (Basel). 2022. PMID: 35062742 Free PMC article.

In light of the availability of the Pfizer-BioNTech BNT162b2 vaccine against COVID-19 for children aged 5-11 years, we aimed to write a position paper for pediatricians, policymakers and families regarding the clinical aspects of COVID-19 and the vaccination of chil …

In light of the availability of the Pfizer-BioNTech BNT162b2 vaccine against COVID-19 for children aged 5-11 years, we aimed t …

87

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination.

Pérez-Then E, Lucas C, Monteiro VS, Miric M, Brache V, Cochon L, Vogels CBF, Malik AA, De la Cruz E, Jorge A, De Los Santos M, Leon P, Breban MI, Billig K, Yildirim I, Pearson C, Downing R, Gagnon E, Muyombwe A, Razeq J, Campbell M, Ko AI, Omer SB, Grubaugh ND, Vermund SH, Iwasaki A. Pérez-Then E, et al. Nat Med. 2022 Mar;28(3):481-485. doi: 10.1038/s41591-022-01705-6. Epub 2022 Jan 20. Nat Med. 2022. PMID: 35051990 Free PMC article.

Here we evaluated the effects of a heterologous BNT162b2 mRNA vaccine booster on the humoral immunity of participants who had received a two-dose regimen of CoronaVac, an inactivated vaccine used globally. ...Although neutralization of Omicron was unde …

Here we evaluated the effects of a heterologous BNT162b2 mRNA vaccine booster on the humoral immunity of participants w …

88

Comprehensive antibody profiling of mRNA vaccination in children.

Bartsch YC, St Denis KJ, Kaplonek P, Kang J, Lam EC, Burns MD, Farkas EJ, Davis JP, Boribong BP, Edlow AG, Fasano A, Shreffler W, Zavadska D, Johnson M, Goldblatt D, Balazs AB, Yonker LM, Alter G. Bartsch YC, et al. bioRxiv [Preprint]. 2022 Jan 4:2021.10.07.463592. doi: 10.1101/2021.10.07.463592. bioRxiv. 2022. PMID: 35018376 Free PMC article. Preprint.

However, whether children respond equivalently to adults to mRNA vaccines and whether dosing will elicit optimal immunity remains unclear. Given the recent announcement of incomplete immunity induced by the pediatric dose of the BNT162b2 vaccine in young chil …

However, whether children respond equivalently to adults to mRNA vaccines and whether dosing will elicit optimal immunity remains unc …

89

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.

Carreño JM, Alshammary H, Tcheou J, Singh G, Raskin AJ, Kawabata H, Sominsky LA, Clark JJ, Adelsberg DC, Bielak DA, Gonzalez-Reiche AS, Dambrauskas N, Vigdorovich V; PSP-PARIS Study Group; Srivastava K, Sather DN, Sordillo EM, Bajic G, van Bakel H, Simon V, Krammer F. Carreño JM, et al. Nature. 2022 Feb;602(7898):682-688. doi: 10.1038/s41586-022-04399-5. Epub 2021 Dec 31. Nature. 2022. PMID: 35016197

Omicron hosts an unprecedented number of mutations in its spike gene and early reports have provided evidence for extensive immune escape and reduced vaccine effectiveness(2,4-6). Here we investigated the virus-neutralizing and spike protein-binding activity of sera from c …

Omicron hosts an unprecedented number of mutations in its spike gene and early reports have provided evidence for extensive immune escape an …

90

Global Perspectives on Immunization Against SARS-CoV-2 During Pregnancy and Priorities for Future Research: An International Consensus Paper From the World Association of Infectious Diseases and Immunological Disorders.

Abu-Raya B, Madhi SA, Omer SB, Amirthalingam G, Giles ML, Flanagan KL, Zimmermann P, O'Ryan M, Safadi MA, Papaevangelou V, Maertens K, Wanlapakorn N, Diaz-Brito V, Tommelein E, Esposito S. Abu-Raya B, et al. Front Immunol. 2021 Dec 23;12:808064. doi: 10.3389/fimmu.2021.808064. eCollection 2021. Front Immunol. 2021. PMID: 35003137 Free PMC article. Review.

91

In-depth Characterization of Vaccine Breakthrough Infections With SARS-CoV-2 Among Health Care Workers in a Dutch Academic Medical Center.

Rümke LW, Groenveld FC, van Os YMG, Praest P, Tanja AAN, de Jong DTCM, Symons J, Schuurman R, Reinders T, Hofstra LM, Nierkens S, Thijsen SFT, Heron M, Lebbink RJ, Beekman JM, Nijhuis M, Wensing AMJ. Rümke LW, et al. Open Forum Infect Dis. 2021 Nov 6;9(1):ofab553. doi: 10.1093/ofid/ofab553. eCollection 2022 Jan. Open Forum Infect Dis. 2021. PMID: 34988250 Free PMC article.

Severe acute respiratory syndrome coronavirus 2 infection after coronavirus disease 2019 vaccination raises concerns about the emergence of vaccine escape variants. Here we characterize 14 breakthrough infections among 5860 fully vaccinated Dutch health care workers 14 day …

Severe acute respiratory syndrome coronavirus 2 infection after coronavirus disease 2019 vaccination raises concerns about the emergence of …

92

High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals.

Tada T, Zhou H, Dcosta BM, Samanovic MI, Cornelius A, Herati RS, Mulligan MJ, Landau NR. Tada T, et al. Cell Rep. 2022 Jan 11;38(2):110237. doi: 10.1016/j.celrep.2021.110237. Epub 2021 Dec 21. Cell Rep. 2022. PMID: 34982967 Free PMC article.

Recently identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants Mu and C.1.2 have spike proteins with mutations that may confer resistance to natural and vaccine-elicited antibodies. Analysis of neutralizing antibody titers in the sera of vaccinat …

Recently identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants Mu and C.1.2 have spike proteins with mutations th …

93

SARS-CoV-2 Delta Variant Breakthrough Infection and Onward Secondary Transmission in Household.

Yi S, Kim JM, Choe YJ, Hong S, Choi S, Ahn SB, Kim M, Park YJ. Yi S, et al. J Korean Med Sci. 2022 Jan 3;37(1):e12. doi: 10.3346/jkms.2022.37.e12. J Korean Med Sci. 2022. PMID: 34981682 Free PMC article.

The primary objective of this study was to investigate the epidemiologic features in infection-vulnerable facilities with a high vaccination rate of BNT162b2 mRNA COVID-19 vaccine. The second was to estimate the secondary transmission prevention effect …

The primary objective of this study was to investigate the epidemiologic features in infection-vulnerable facilities with a high vaccination …

94

Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel.

Prunas O, Warren JL, Crawford FW, Gazit S, Patalon T, Weinberger DM, Pitzer VE. Prunas O, et al. medRxiv [Preprint]. 2021 Dec 20:2021.07.13.21260393. doi: 10.1101/2021.07.13.21260393. medRxiv. 2021. Update in: Science. 2022 Mar 11;375(6585):1151-1154. doi: 10.1126/science.abl4292 PMID: 34981074 Free PMC article. Updated. Preprint.

However, few studies have directly examined the effect of COVID-19 vaccines on transmission. We quantified the effectiveness of vaccination with BNT162b2 (Pfizer-BioNTech mRNA-based vaccine) against household transmission of SARS-CoV-2 in Israel …

However, few studies have directly examined the effect of COVID-19 vaccines on transmission. We quantified the effectiveness of vacci …

95

Postvaccination SARS-COV-2 among Health Care Workers in New Jersey: A Genomic Epidemiological Study.

Mathema B, Chen L, Chow KF, Zhao Y, Zody MC, Mediavilla JR, Cunningham MH, Composto K, Lee A, Oschwald DM, Germer S, Fennessey S, Patel K, Wilson D, Cassell A, Pascual L, Ip A, Corvelo A, Dar S, Kramer Y, Maniatis T, Perlin DS, Kreiswirth BN. Mathema B, et al. Microbiol Spectr. 2021 Dec 22;9(3):e0188221. doi: 10.1128/Spectrum.01882-21. Epub 2021 Nov 17. Microbiol Spectr. 2021. PMID: 34787439 Free PMC article.

Emergence of SARS-CoV-2 with high transmission and immune evasion potential, the so-called variants of concern (VOC), is a major concern. ...From 1 January 2021 to 30 April 2021, 23,687 HCPs received either mRNA-1273 or BNT162b2 mRNA vaccine. Al …

Emergence of SARS-CoV-2 with high transmission and immune evasion potential, the so-called variants of concern (VOC), is a major conc …

96

The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021.

Zuckerman N, Nemet I, Kliker L, Atari N, Lustig Y, Bucris E, Bar Ilan D, Geva M, Sorek-Abramovich R, Weiner C, Rainy N, Bar-Chaim A, Benveniste-Levkovitz P, Abu Hamed R, Regev-Yochay G, Hevkin O, Mor O, Alroy-Preis S, Mendelson E, Mandelboim M. Zuckerman N, et al. Euro Surveill. 2021 Nov;26(45):2100974. doi: 10.2807/1560-7917.ES.2021.26.45.2100974. Euro Surveill. 2021. PMID: 34763751 Free PMC article.

First detected in Israel in April 2021 following importations from Argentina and several European countries, the Lambda variant infected 18 individuals belonging to two main transmission chains without further spread. Micro-neutralisation assays following Comirnaty (BNT …

First detected in Israel in April 2021 following importations from Argentina and several European countries, the Lambda variant infected 18 …

97

The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5-11 Years - United States, November 2021.

Woodworth KR, Moulia D, Collins JP, Hadler SC, Jones JM, Reddy SC, Chamberland M, Campos-Outcalt D, Morgan RL, Brooks O, Talbot HK, Lee GM, Bell BP, Daley MF, Mbaeyi S, Dooling K, Oliver SE. Woodworth KR, et al. MMWR Morb Mortal Wkly Rep. 2021 Nov 12;70(45):1579-1583. doi: 10.15585/mmwr.mm7045e1. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34758012 Free PMC article.

The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. ...Vaccination is important to protect childre …

The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine …

98

Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants.

McCallum M, Walls AC, Sprouse KR, Bowen JE, Rosen LE, Dang HV, De Marco A, Franko N, Tilles SW, Logue J, Miranda MC, Ahlrichs M, Carter L, Snell G, Pizzuto MS, Chu HY, Van Voorhis WC, Corti D, Veesler D. McCallum M, et al. Science. 2021 Dec 24;374(6575):1621-1626. doi: 10.1126/science.abl8506. Epub 2021 Nov 9. Science. 2021. PMID: 34751595 Free article.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission leads to the emergence of variants, including the B.1.617.2 (Delta) variant of concern that is causing a new wave of infections and has become globally dominant. We show that these variants dampen th …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission leads to the emergence of variants, including the B.1.617.2 …

99

The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus.

Maldonado MD, Romero-Aibar J. Maldonado MD, et al. Brain Behav Immun Health. 2021 Dec;18:100381. doi: 10.1016/j.bbih.2021.100381. Epub 2021 Oct 30. Brain Behav Immun Health. 2021. PMID: 34746880 Free PMC article.

BACKGROUND: To prevent the invasion and transmission of SARS-CoV-2, mRNA-based vaccines, non-replicating viral vector vaccines, and inactivated vaccines have been developed. ...RESULTS: Two patients, a 79-year-old man and a 56-year-old woman, are reported who, after …

BACKGROUND: To prevent the invasion and transmission of SARS-CoV-2, mRNA-based vaccines, non-replicating viral vector vaccines …

100

A snapshot global survey on side effects of COVID-19 vaccines among healthcare professionals and armed forces with a focus on headache.

Perrotta A, Biondi-Zoccai G, Saade W, Miraldi F, Morelli A, Marullo AG, Cavarretta E, Carnevale R, DE Falco E, Chimenti I, Sciarretta S, Frati P, Mamas MA, Ciardi S, Frati L, Frati G, Peruzzi M. Perrotta A, et al. Panminerva Med. 2021 Sep;63(3):324-331. doi: 10.23736/S0031-0808.21.04435-9. Panminerva Med. 2021. PMID: 34738774 Free article.

BACKGROUND: New messenger RNA (mRNA) and adenovirus-based vaccines (AdV) against Coronavirus disease 2019 (COVID-19) have entered large scale clinical trials. ...RESULTS: A total of 375 complete surveys have been analyzed. More than 88% received an mRNA …

BACKGROUND: New messenger RNA (mRNA) and adenovirus-based vaccines (AdV) against Coronavirus disease 2019 (COVID-19) ha …

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

142 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Results by year